Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by youngpupperon Sep 06, 2018 10:16am

89 Views

Post# 28571493

RE:RE:RE:RE:RE:ANTIBE LONGs rewarded for patience!

Where are you getting 30M number from? I find it hard to believe a phase 3 with a general pain reliever as the investigational drug has a cost similar to new cancer drugs. The endpoints are far less expensive to measure and the personel/facilities required to oversee the study won't be as expensive. Take the phase 2A and maybe double the cost.

Bullboard Posts

Golden Minerals closes Yoquivo gold-silver project sale